Montreal Device Uses AI to Revolutionize Cancer Surgery and Save Lives

A groundbreaking surgical device developed in Montreal is transforming cancer treatment by using artificial intelligence (AI) to significantly improve patient outcomes. The device, known as SENTRY, assists surgeons in distinguishing between cancerous and healthy tissue, offering hope to patients like Peter Ross, who was given just 14 months to live after being diagnosed with a brain tumor nearly four years ago.

Ross, now preparing to become a grandfather, attributes his extended life to this innovative technology. “It’s given me the rest of my life,” he expressed, reflecting on his journey. His wife, Sandrine Menard, echoed his sentiment, stating, “Whatever happens, we’re grateful.”

How SENTRY Works

The SENTRY device, co-founded by surgeon Dr. Kevin Petrecca at the Montreal Neuro, allows for real-time identification of tumor cells during surgery. According to Petrecca, “98.7 percent of the time, if it says it’s tumor, it’s tumor.” Even more crucially, when the device indicates normal brain tissue, it is correct 100 percent of the time.

This technology addresses a significant challenge in cancer surgeries, where tumors often remain undetectable to the naked eye and traditional imaging techniques. With SENTRY, surgeons can receive feedback in less than three seconds, enabling them to remove more cancerous tissue than previously possible. Petrecca noted that utilizing this device can potentially extend a patient’s life two to five times longer than expected.

While SENTRY has primarily been tested in brain surgeries, its applications extend to other cancers, including those affecting the breast and lungs. Hundreds of patients have participated in clinical trials, including Ross, who shared, “I take every extra day that’s given to me to go out and walk, and just enjoy life because I owe that to this surgery.”

Next Steps for SENTRY

As SENTRY moves closer to becoming a standard tool in surgical oncology, the next critical phase is obtaining approval from the FDA. A pivotal trial is set for May 2024, and Ross hopes that this advancement will grant more patients the opportunity to reach significant life milestones.

The story of Peter Ross and the SENTRY device highlights the potential of combining technology with medicine to not only enhance surgical precision but also to profoundly impact patients’ lives. As this innovation progresses through regulatory approval, it stands to change the landscape of cancer treatment and provide hope to many more individuals facing similar diagnoses.